ArticleJournal of clinical practice and research2024
Vitamin D Levels Are Associated With Pain and Pain Catastrophizing in Patients With Fibromyalgia Syndrome.
Article in Journal of clinical practice and research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Vitamin D in Neuropathic Pain: Biological Mechanisms and Clinical Relevance.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Low vitamin D (VD) levels may increase pain sensitivity, particularly by enhancing central sensitivity. Fibromyalgia is associated with disruptions in neurotransmitters and inflammatory pathways within the central nervous system, leading to an increased sensitivity of pain signals. This study aimed to investigate the relationship between vitamin D levels and pain, pain catastrophizing, function, depression, and anxiety. Materials and Methods: This study included 153 patients with Fibromyalgia Syndrome (FMS) and 153 healthy individuals. Vitamin D levels were measured using 5 ml blood samples obtained from both patients and healthy individuals. The Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS), McGill Pain Questionnaire-Short Form (MPQ), and Fibromyalgia Impact Questionnaire (FIQ) were used to evaluate pain, pain catastrophizing, psychological symptoms, and function, respectively. Results: VD levels were statistically lower in the FMS group (17.71±9.32 ng/ml) compared to the control group (20.40±9.33 ng/ml) (p<0.05). No statistical difference was found among groups classified according to vitamin D subgroups in terms of FIQ, MPQ, PCS, and HADS scores (p>0.05). There was a negative correlation between VD levels and MPQ, as well as all subgroups of PCS (p>0.05), while no significant correlation was found between VD levels and depression, anxiety, or function. Conclusion: VD levels in patients with FMS were found to be lower than those in healthy individuals, and VD levels were associated with pain and pain catastrophizing in this study. Physician-supervised VD supplementation may improve pain catastrophizing in patients with FMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.